Home > News > Lumiphore and Echelon Biosciences Introduce Novel Cancer Assays
April 4th, 2006
Lumiphore and Echelon Biosciences Introduce Novel Cancer Assays
Abstract:
Lumiphore Inc. and Echelon Biosciences Inc. jointly announce the finalization of a license agreement that provides Echelon access to Lumiphore's proprietary lanthanide-complex technology for the development of TR-FRET assays and reagents for use in research and drug discovery in the field of phospholipid signaling and lipid-protein interactions.
Source:
prnewswire
Bookmark:
| Related Links |
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||